Results 31 to 40 of about 364,790 (104)

Nonlytic Fc-fused IL-7 synergizes with Mtb32 DNA vaccine to enhance antigen-specific T cell responses in a therapeutic model of tuberculosis

, 2013
Improvement to the immunogenicity of DNA vaccines was evaluated in a Mycobacterium tuberculosis (MTB) infection mouse model examining the combined effects of nonlytic Fc-fused IL-7 DNA (IL-7-nFc) and Flt3-ligand fused Mtb32 (F-Mtb32) DNA.
조상래
core   +1 more source

Vaccine effectiveness estimates, 2004-2005 mumps outbreak, England. [PDF]

, 2007
The United Kingdom and United States have recently experienced large outbreaks of mumps, which raises concerns about vaccine effectiveness. The effectiveness of the mumps component of the measles, mumps, rubella (MMR) vaccine was estimated using the ...
Savage, Emma J, Cheryl Cohen, Judith R. Glynn, Andrews, Nick, Ramsay, Mary E, Cohen, Cheryl, Brown, David, Joanne M. White, Glynn, Judith R, Emma J. Savage, Choi, Yoon, David Brown, White, Joanne M, Yoon Choi, Mary E. Ramsay, Nick Andrews   +15 more
core   +1 more source

Varicella Breakthrough Infection and Vaccine Effectiveness in Taiwan

, 2012
We performed this nationwide retrospective investigation among the recipients of varicella vaccine to evaluate the breakthrough varicella infection rate, factors associated with breakthrough infection and the vaccine effectiveness.
HUANG, WEN-CHAN;HUANG, LI-MIN;CHANG, I-SHOU;TSAI, FANG-YU;CHANG, LUAN-YIN, 黃文嬋;黃立民;張憶壽;蔡芳榆;張鑾英   +1 more
core   +1 more source

Assessment of parental perception of malaria vaccine in Tanzania [PDF]

, 2015
Clinical trials of the RTS,S malaria vaccine have completed Phase III and the vaccine is on track for registration. Before making decisions about implementation, it is essential to prepare the ground for introducing the vaccine by assessing awareness and
Marcel Tanner, Idda Romore, Hassan Mshinda, Abdulla, Salim, Romore, Idda, Ali Mohamed Ali, Salim Abdulla, Semali, Innocent, Ali, Ali Mohamed, Innocent Semali, Mshinda, Hassan, Tanner, Marcel, Mshinda H, Ali AM, Semali I, Abdulla S, Tanner M, Romore I   +17 more
core   +1 more source

Malaria vaccine research and development: the role of the WHO MALVAC committee. [PDF]

, 2013
The WHO Malaria Vaccine Advisory Committee (MALVAC) provides advice to WHO on strategic priorities, activities and technical issues related to global efforts to develop vaccines against malaria.
Vasee S Moorthy, Graham V Brown, Geoffrey AT Targett, Targett, Geoffrey AT, Brown, GV, Moorthy, Vasee S, Brown, Graham V, Geoffrey AT Targett, Moorthy, VS, Targett, GA   +9 more
core   +1 more source

A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity [PDF]

, 2012
© 2012 Elsevier Ltd. All rights reservedBackground: The development of a new, more effective vaccine against tuberculosis (TB) for use in healthy and HIV-infected adults, children and infants, remains a global health priority.
Sander, C, Angela M Minassian, Nicola Williams, Lawrie, AM, Alison M Lawrie, Rowland, R, Poulton, ID, Rosalind Rowland, Brittain, N, Pathan, AA, David W Porter, Minassian, AM, Helen McShane, Iman Satti, Ansar A Pathan, Ian D Poulton, Nathaniel Brittain, Williams, N, Clare Sander, Porter, DW, Satti, I, McShane, H   +21 more
core   +1 more source

Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine

, 2012
Adults 40 years of age and older have been shown to be hypo-responsive immunologically to the currently available hepatitis B virus (HBV) vaccines. Three intramuscular doses of a Toll-like receptor 9 agonist, 1018 immunostimulatory sequence (1018 ISS ...
안상훈
core  

First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. [PDF]

, 2011
BACKGROUND\ud \ud An ongoing phase 3 study of the efficacy, safety, and immunogenicity of candidate malaria vaccine RTS,S/AS01 is being conducted in seven African countries.\ud \ud METHODS\ud \ud From March 2009 through January 2011, we enrolled 15,460 ...
Machera, Francisca, Abdulla, Salim, Sillman, Marla, Maingi, Charity, Aide, Pedro, Kremsner, Peter Gottfried, Conzelmann, Cornelia, Adjei, George, Abdul, Omari, Leach, Amanda, Methogo, Barbara Gaelle Nfono Ondo, Bejon, Philip, Gondi, Stacey, Chome, Nelecy, Doucka, Yannick, Aponte, John J, Guerra, Yolanda, Chandramohan, Daniel, null null, Jones, David, Liheluka, Edwin, Loucq, Christian, Omoto, Jackton, Nyakuipa, Dalitso, Flamen, Arnaud, Jongert, Erik, Otieno, Walter, Bassat, Quique, Mordmüller, Benjamin, Slutsker, Laurence, Agyekum, Alex, Ofori-Anyinam, Opokua, Hamad, Ali Said, Wasuna, Ruth, Vansadia, Preeti, Lanaspa, Miguel, Drakeley, Chris, Kaboré, William, Asante, Isaac, Gesase, Samwel, Cohen, Joe, Shubis, Kafuruki, Ogutu, Bernhards, Agnandji, Selidji Todagbe, Otieno, Lucas, Sambian, David, Ansong, Daniel, Lell, Bertrand, Awino, Norbert, Gitaka, Jesse, Carter, Terrell, Juma, Omar, Shomari, Mwanajaa, Hoffman, Irving, Mtoro, Ali, Schellenberg, David, Quelhas, Diana, Radford, Afiya, Minja, Rose, Kerubo, Christine, Theander, Thor, Ahmed, Saumu, Odero, Chris, Vekemans, Johan, Nkomo, Ruthendo, Muturi-Kioi, Vincent, Mvalo, Tisungane, RTS,S Clinical Trials Partnership, Tsofa, Benjamin, Dosoo, David, Ouédraogo, Jean Bosco, Mwangoka, Grace, Rettig, Theresa, Sorgho, Hermann, Ouédraogo, Sayouba, Osei-Kwakye, Kingsley, Agbenyega, Tsiri, Owira, Victorine, Issifou, Saadou, Kariuki, Simon, Oneko, Martina, Otieno, Kephas, Olotu, Ally, Lapierre, Didier, Fernandes, José Francisco, Ali, Ali Mohammed, Boahen, Owusu, Onyango, Agnes Akoth, Sylverken, Justice, Hamel, Mary J, Macete, Eusébio, Asante, Kwaku Poku, Owusu-Agyei, Seth, Lemnge, Martha, Ayamba, Samuel, Msika, Albans, Kayan, Kingsley, Alonso, Pedro, Kamthunzi, Portia, Otieno, Allan, Ballou, W Ripley, Nekoye, Otsyula, Lievens, Marc, Abossolo, Béatrice Peggy, Mandjate, Sofia, Marsh, Kevin, Urassa, Alwisa Martin, Mahende, Coline, Bawa, John, Sandrine, Yara, Akoo, Pauline, Adjei, Samuel, Njuguna, Patricia, Jumbe, Allan, Williamson, John, Leboulleux, Didier, Greenwood, Brian, Malabeja, Anangisye, Chilengi, Roma, Nhamuave, Arlindo, Guiguemdé, Robert Tinga, Tinto, Halidou, Tahita, Marc Christian, Martinson, Francis, Kilavo, Hassan, Lusingu, John, Boateng, Harry Owusu, Chintedza, Joseph, Soulanoudjingar, Solange Solmeheim, Lang, Trudie, Sacarlal, Jahit, Bruls, Myriam, The RTS, S. Clinical Trials Partnership, Sykes, Alma, Owusu, Larko, Tanner, Marcel, Laserson, Kayla F, Peshu, Norbert, Savarese, Barbara, Owusu-Ofori, Ruth, Valea, Innocent, D'Alessandro, Umberto, Salim, Nahya   +142 more
core   +1 more source

A Phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine

, 2013
[[abstract]]AbstractBackground Large-scale outbreaks of enterovirus 71 (EV71) infections have occurred in Asia-Pacific regions. Severe complications include encephalitis and poliomyelitis-like paralysis, cardiopulmonary collapse, and death, necessitating
Cheng, A;Fung, CP;Liu, CC;Lin, YT;Tsai, HY;Chang, SC;Chou, AH;Chang, JY;Jiang, RH;Hsieh, YC;Su, IJ;Chong, PCS;Hsieh, SM
core   +1 more source

A phase 2a randomized study to evaluate the safety and immunogenicity of the 1790GAHB GMMA vaccine against Shigella sonnei administered intramuscularly to adults from a shigellosis-endemic country

, 2017
Shigellosis is a mild-to-severe diarrheal infection caused by the genus Shigella and responsible for significant morbidity and mortality worldwide. We evaluated the safety and immunogenicity of an investigational Shigella sonnei vaccine (1790GAHB) based on Generalized Modules for Membrane Antigens (GMMA) in Kenya, a Shigella-endemic country. This phase
Obiero, C, Ndiaye, A, Scirè, A, Kaunyangi, B, Marchetti, E, Gone, A, Schütte, L, Riccucci, D, Auerbach, J, Saul, A, Martin, L, Bejon, P, Njuguna, P, Podda, A   +13 more
openaire   +1 more source